Mohini Rajasagi

Mohini Rajasagi currently serves as the Executive Director and Head of Oncology Translational Strategy and Execution (Late Stage) at Daiichi Sankyo, Inc. since July 2022. Prior to this role, Mohini held positions at Merck where responsibilities included Sr. Director and Director of Oncology Translational Science and Clinical Biomarkers from September 2018 to July 2022. Mohini's experience also encompasses a position as Principal Scientist/Research Project Leader at Pfizer, and as a Research Investigator in Immuno-Oncology Discovery at Bristol-Myers Squibb. Mohini began a career in research as an Immuno-Oncology Postdoctoral Research Fellow at Dana-Farber Cancer Institute from July 2009 to March 2014. Academically, Mohini earned a Ph.D. in Immuno-Oncology from the German Cancer Research Center in Heidelberg, Germany, an MSc in Biotechnology from the University of Essex, and a BSc in Biotechnology, Biochemistry, and Genetics from Bangalore University.